Examkin

Question

Difficulty: MediumPreventive Care and Screening

A 34-year-old woman presents to the clinic for a routine health maintenance visit. Six months ago, she was diagnosed with Crohn disease involving the terminal ileum and colon. Her disease is currently in clinical remission on a maintenance regimen of infliximab and azathioprine. She feels well and reports no abdominal pain, diarrhea, or weight loss. She works as a high school teacher. Review of her immunization records reveals she received all standard childhood vaccines but has not received any immunizations since age 18. Laboratory evaluation shows negative varicella-zoster virus IgG antibodies. Her vital signs and physical examination today are unremarkable. Which of the following is the most appropriate next step in the preventive management of this patient?

  1. Administer the 20-valent pneumococcal conjugate vaccineAnswer
  2. B
    Administer the live-attenuated varicella vaccine
  3. C
    Schedule a screening colonoscopy
  4. D
    Order a computed tomography scan of the abdomen and pelvis
  5. E
    Delay all routine immunizations until immunosuppressive therapy is discontinued

Answer

Administer the 20-valent pneumococcal conjugate vaccine
The correct intervention is to administer the 20-valent pneumococcal conjugate vaccine. Patients receiving immunosuppressive medications, such as the tumor necrosis factor (TNF) inhibitor infliximab and the antimetabolite azathioprine, have an acquired immunodeficiency. This places them at a significantly increased risk for severe, invasive pneumococcal disease. Current guidelines explicitly recommend pneumococcal vaccination for adults aged 19 to 64 years with immunocompromising conditions. Because the pneumococcal conjugate vaccine is an inactivated (non-live) vaccine, it is safe to administer while the patient is actively taking these medications and will provide crucial protection.

Step-by-Step Solution

1
Identify the patient's immune status based on her medication history.
The patient is actively taking infliximab and azathioprine, which means she is significantly immunocompromised.
Immune status dictates both the indications for specific vaccines (e.g., pneumococcal) and the absolute contraindications (e.g., live-attenuated vaccines).
2
Determine the indication for pneumococcal vaccination.
Pneumococcal vaccination is indicated.
Guidelines recommend pneumococcal vaccination for all adults aged 19 to 64 years with immunocompromising conditions, including iatrogenic immunosuppression.
3
Evaluate the safety of the proposed interventions.
The 20-valent pneumococcal conjugate vaccine is an inactivated vaccine and is safe to administer. The varicella vaccine is a live vaccine and is strictly contraindicated.
Live-attenuated vaccines can cause uncontrolled viral replication and disseminated disease in immunocompromised hosts.

Key Concept

Inactivated vaccines (e.g., pneumococcal conjugate) are indicated and safe for immunocompromised patients, whereas live-attenuated vaccines (e.g., varicella) are absolutely contraindicated.
Rate this question

Topics

Preventive Care and Screening

More questions from this topic